This study looks at the long-term safety and effectiveness of a medicine called pirtobrutinib. This research includes people who have taken part in earlier studies of pirtobrutinib for conditions like Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma. Participants can continue their treatment and follow-up visits as part of this study.
The trial's ID number is NCT06876649. It is a Phase 4 trial, which means it is looking at how well the treatment works and how safe it is. This study is regulated by the FDA and aims to include about 787 participants.
Who can join
Adults aged 18 and older can join if they are part of a Lilly-sponsored study testing pirtobrutinib. Both men and women can participate. The trial team will confirm who is eligible to join.
The study team makes the final call on eligibility.
What happens in the study
Participants will take pirtobrutinib as part of a single group. This medicine is given by mouth. There is no random assignment to different groups in this study.
Where
This trial is enrolling at 20 locations. Recruiting sites are listed first.
Cayuga Cancer Center
Ithaca, New York
Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts
Recruiting
Duke University Medical Center
Durham, North Carolina
Recruiting
Florida Cancer Specialists
Sarasota, Florida
Recruiting
Mayo Clinic- Minnesota
Rochester, Minnesota
Recruiting
Medical College of Wisconsin
Milwaukee, Wisconsin
Recruiting
Memorial Sloan-Kettering Cancer Center (MSKCC) - New York
New York, New York
Recruiting
Northwell Health
Lake Success, New York
Recruiting
Study contact
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Elected to the National Academy of Medicine. Treats leukemia and myelodysplastic syndrome. The main doctor for adults with blood cancers, like leukemia, lymphoma, and myeloma. Recognized at state, national or international level.
Professor and transplant specialist, UC Davis. Treats leukemia, lymphoma and multiple myeloma. The main doctor for adults with blood cancers, like leukemia, lymphoma, and myeloma. Recognized at state, national or international level.